Quest PharmaTech Inc. (QPTFF)
OTCMKTS · Delayed Price · Currency is USD
0.0133
-0.0017 (-11.33%)
At close: Jul 15, 2024
Quest PharmaTech Company Description
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer.
The company’s lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16 for the potential cancer targets, including pancreatic, colon, leukemia, ovarian, and breast cancer.
Quest PharmaTech Inc. is headquartered in Edmonton, Canada.
Quest PharmaTech Inc.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Ragupathy Madiyalakan |
Contact Details
Address: 97 Street NW Edmonton, Alberta T6E 5R9 Canada | |
| Phone | 780 448 1400 |
| Website | questpharmatech.com |
Stock Details
| Ticker Symbol | QPTFF |
| Exchange | OTCMKTS |
| Fiscal Year | February - January |
| Reporting Currency | CAD |
| ISIN Number | CA74836M1068 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ragupathy Madiyalakan Ph.D. | Chief Executive Officer and Director |
| Pierre Vermette C.A., CPA | Chief Financial Officer |
| Roger Andrews | Head of Investor Relations and Corporate Communications |
| Douglas C. Bachman | Vice President of Corporate Development |
| Thomas Woo | Vice President of Product Development |